In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains

IF 2.1 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Journal of Antibiotics Pub Date : 2024-05-08 DOI:10.1038/s41429-024-00734-2

Alicja Sękowska

{"title":"In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains","authors":"Alicja Sękowska","doi":"10.1038/s41429-024-00734-2","DOIUrl":null,"url":null,"abstract":"Plazomicin is a new aminoglycoside with broad-spectrum activity against multidrug-resistant strains. The aim of this study was to assess the susceptibility of the K. pneumoniae strains to plazomicin and other aminoglycosides. The activity of plazomicin in combination with ceftazidim-avibactam or meropenem with selected strains was evaluated. The study involved 60 ESβL-positive K. pneumoniae isolates and 50 carbapenemase-positive. The susceptibility to aminoglycosides was tested using the gradient strip. The in vitro activities of plazomicin and ceftazidim-avibactam or meropenem were evaluated using the MTSTM cross synergy method. Plazomicin exhibited high activity against K. pneumoniae with MICs ranging from 0.19 to 4 µg ml−1 for ESβL-positive strains and from 0.25 to 256 µg ml−1 for carbapenemase-positive strains. No antagonism was identified with any combinations. Plazomicin demonstrated excellent in vitro activity against analyzed strains, suggesting that this antibiotic may be an effective therapeutic option in the treatment of infections caused by MDR K. pneumoniae strains.","PeriodicalId":54884,"journal":{"name":"Journal of Antibiotics","volume":"77 8","pages":"548-551"},"PeriodicalIF":2.1000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Antibiotics","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41429-024-00734-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Plazomicin is a new aminoglycoside with broad-spectrum activity against multidrug-resistant strains. The aim of this study was to assess the susceptibility of the K. pneumoniae strains to plazomicin and other aminoglycosides. The activity of plazomicin in combination with ceftazidim-avibactam or meropenem with selected strains was evaluated. The study involved 60 ESβL-positive K. pneumoniae isolates and 50 carbapenemase-positive. The susceptibility to aminoglycosides was tested using the gradient strip. The in vitro activities of plazomicin and ceftazidim-avibactam or meropenem were evaluated using the MTSTM cross synergy method. Plazomicin exhibited high activity against K. pneumoniae with MICs ranging from 0.19 to 4 µg ml−1 for ESβL-positive strains and from 0.25 to 256 µg ml−1 for carbapenemase-positive strains. No antagonism was identified with any combinations. Plazomicin demonstrated excellent in vitro activity against analyzed strains, suggesting that this antibiotic may be an effective therapeutic option in the treatment of infections caused by MDR K. pneumoniae strains.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

普拉唑霉素和其他氨基糖苷类药物对肺炎克雷伯氏菌耐多药菌株的体外活性

Plazomicin 是一种新型氨基糖苷类药物，具有广谱抗耐多药菌株的活性。这项研究的目的是评估肺炎克雷伯菌株对他唑霉素和其他氨基糖苷类药物的敏感性。研究还评估了普拉唑霉素与头孢他啶-阿维巴坦或美罗培南联用对部分菌株的活性。研究涉及 60 株 ESβL 阳性的肺炎克雷伯菌分离株和 50 株碳青霉烯酶阳性的分离株。使用梯度条测试了对氨基糖苷类药物的敏感性。使用 MTSTM 交叉协同法对普拉唑霉素和头孢他啶-阿维巴坦或美罗培南的体外活性进行了评估。普拉唑霉素对肺炎克氏菌具有很高的活性，对 ESβL 阳性菌株的 MIC 为 0.19 至 4 µg ml-1，对碳青霉烯酶阳性菌株的 MIC 为 0.25 至 256 µg ml-1。任何组合均未发现拮抗作用。普拉佐米星对所分析的菌株具有出色的体外活性，这表明这种抗生素可能是治疗由MDR肺炎克氏菌菌株引起的感染的一种有效疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Antibiotics 医学-免疫学

CiteScore

6.60

自引率

3.00%

发文量

审稿时长

1 months

期刊介绍： The Journal of Antibiotics seeks to promote research on antibiotics and related types of biologically active substances and publishes Articles, Review Articles, Brief Communication, Correspondence and other specially commissioned reports. The Journal of Antibiotics accepts papers on biochemical, chemical, microbiological and pharmacological studies. However, studies regarding human therapy do not fall under the journal’s scope. Contributions regarding recently discovered antibiotics and biologically active microbial products are particularly encouraged. Topics of particular interest within the journal''s scope include, but are not limited to, those listed below: Discovery of new antibiotics and related types of biologically active substances Production, isolation, characterization, structural elucidation, chemical synthesis and derivatization, biological activities, mechanisms of action, and structure-activity relationships of antibiotics and related types of biologically active substances Biosynthesis, bioconversion, taxonomy and genetic studies on producing microorganisms, as well as improvement of production of antibiotics and related types of biologically active substances Novel physical, chemical, biochemical, microbiological or pharmacological methods for detection, assay, determination, structural elucidation and evaluation of antibiotics and related types of biologically active substances Newly found properties, mechanisms of action and resistance-development of antibiotics and related types of biologically active substances.